June 28, 2021
4 min watch
Save
VIDEO: Efpeglenatide reduces risk for major adverse CV events in type 2 diabetes
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video exclusive, Richard E. Pratley, MD, the Samuel E. Crockett chair in diabetes research and medical director of AdventHealth Diabetes Institute, announces results from the AMPLITUDE-O cardiovascular outcomes study of the exendin-based GLP-1 receptor agonist efpeglenatide.
Weekly injection with efpeglenatide resulted in reductions in HbA1c, blood pressure and BMI vs. placebo. It also was associated with a significant 27% reduction in risk for major adverse cardiovascular events among adults with type 2 diabetes at high risk for CVD — “one of the most robust reductions in MACE events observed [in the GLP-1 class],” Pratley said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio interview
Disclosures:
Pratley reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.